Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells.

Wang, Yulu; Sharma, Amit; Ge, Fangfang; Chen, Peng; Yang, Yu; Liu, Hongjia; Liu, Hongde; Zhao, Chunxia; Mittal, Lovika; Asthana, Shailendra; Schmidt-Wolf, Ingo G H

Wang, Yulu; Sharma, Amit; Ge, Fangfang; Chen, Peng; Yang, Yu; Liu, Hongjia; Liu, Hongde; Zhao, Chunxia; Mittal, Lovika; Asthana, Shailendra; Schmidt-Wolf, Ingo G H.

Afiliação

Wang Y; Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
Sharma A; Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
Ge F; Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.
Chen P; Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
Yang Y; Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
Liu H; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Liu H; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Zhao C; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Mittal L; School of Nursing, Nanchang University, Nanchang, China.
Asthana S; Translational Health Science and Technology Institute (THSTI), NCR Biotech Science Cluster, Faridabad, Haryana, India.
Schmidt-Wolf IGH; Translational Health Science and Technology Institute (THSTI), NCR Biotech Science Cluster, Faridabad, Haryana, India.